Evaluating the anti-angiogenic properties of Iloprost and Dipyridamole in the chick embryo chorioallantoic membrane model

Basit Öğe Kaydı
dc.contributor.authorGuclu, Orkut
dc.contributor.authorKarahan, Oguz
dc.contributor.authorYazici, Suleyman
dc.contributor.authorCaliskan, Ahmet
dc.contributor.authorDemirtas, Sinan
dc.contributor.authorYavuz, Celal
dc.contributor.authorMuratoglu, Abdurrahman
dc.date.accessioned2024-04-24T17:40:19Z
dc.date.available2024-04-24T17:40:19Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractDipyridamole is an antithrombotic agent that is widely used in the treatment of many vascular disorders. Also, the prostacyclin analogue iloprost has been utilized to salvage limbs in patients with severe limb ischemia. In this study we investigated whether dipyridamole and iloprost have anti-angiogenic properties and their anti-angiogenic properties were compared to bevacizumab, a known inhibitor of angiogenesis, using the in vivo chick chorioallantoic membrane animal model. Agar pellets were prepared with three different drug concentrations at 10(-6) M, 10(-5) M, and 10(-4) M. For each drug concentration twenty fertilized eggs were used. The entire experiment was performed in duplicate. Blood vessel density and loss were examined and scored under a stereoscopic microscope. For the 10(-4) M, 10(-5) M and 10(-6) M concentrations, the anti-angiogenic scores of iloprost were 0.2, 0.1 and 0.05, respectively. In the same order, the anti-angiogenic scores for dipyridamole were 0.2, 0.3 and 0.8. The antiangiogenic scores for bevacizumab were significantly higher than dipyridamole and iloprost over all concentrations (p<0.05). There were no significant differences found between the anti-angiogenic scores for iloprost and dipyridamole for all concentrations (p>0.05). Iloprost demonstrated no anti-angiogenic properties in the chorioallantoic membrane animal model, while dipyridamole did exhibit very weak anti-angiogenic activity only at very high doses of 10(-4) M. These results reveal that both agents can be prescribed safely for the treatment of medical conditions that require angiogenesis to facilitate healing.en_US
dc.identifier.endpage370en_US
dc.identifier.issn0970-938X
dc.identifier.issn0976-1683
dc.identifier.issue3en_US
dc.identifier.startpage365en_US
dc.identifier.urihttps://hdl.handle.net/11468/21747
dc.identifier.volume25en_US
dc.identifier.wosWOS:000342566800016
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherAllied Acaden_US
dc.relation.ispartofBiomedical Research-India
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectIloprosten_US
dc.subjectDipyridamoleen_US
dc.subjectBevacizumaben_US
dc.subjectAngiogenesisen_US
dc.subjectChorioallantoic Membrane Modelen_US
dc.titleEvaluating the anti-angiogenic properties of Iloprost and Dipyridamole in the chick embryo chorioallantoic membrane modelen_US
dc.titleEvaluating the anti-angiogenic properties of Iloprost and Dipyridamole in the chick embryo chorioallantoic membrane model
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu